Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2024. The report is now available to download at For further information, please contact: Viktor ...

Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical phase 1b/2a trial evaluating the ...

Karolinska Development AB (publ) STOCKHOLM, SWEDEN – March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided ...

Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical ...

STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an ...

Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug candidate, PN6047, in a pre-IND meeting ...

STOCKHOLM, SWEDEN - March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

STOCKHOLM, SWEDEN, February 18 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of ...

STOCKHOLM, SWEDEN - March 12, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug ...